Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging public health concern intricately linked to metabolic syndrome and cardiovascular diseases. Among its complications, MASLD is associated with progressive liver fibrosis and an elevated risk of adverse cardiovascular outcomes, including coronary artery disease (CAD), congestive heart failure (CHF), and peripheral artery disease (PAD). Patients with [...]